Chardan Capital Raises Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $80.00

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price objective hoisted by equities researchers at Chardan Capital from $60.00 to $80.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price objective would indicate a potential upside of 12.98% from the company’s current price.

Several other equities research analysts have also recently issued reports on ARWR. The Goldman Sachs Group lifted their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 20th. Bank of America lifted their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Royal Bank Of Canada raised their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Finally, Morgan Stanley upped their price target on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a report on Wednesday, November 26th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $64.11.

Arrowhead Pharmaceuticals Stock Up 10.8%

Shares of Arrowhead Pharmaceuticals stock opened at $70.81 on Wednesday. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $76.76. The company has a market capitalization of $9.62 billion, a P/E ratio of -885.01 and a beta of 1.21. The company has a 50 day moving average of $55.83 and a 200 day moving average of $35.74.

Insiders Place Their Bets

In related news, COO Patrick O’brien sold 49,493 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the sale, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at $29,971,443.88. This represents a 9.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James C. Hamilton sold 40,164 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $2,534,750.04. Following the transaction, the insider directly owned 171,958 shares in the company, valued at approximately $10,852,269.38. This trade represents a 18.93% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 510,836 shares of company stock worth $33,603,060. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ARWR. GAMMA Investing LLC grew its position in Arrowhead Pharmaceuticals by 39.0% during the 4th quarter. GAMMA Investing LLC now owns 3,649 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 1,023 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Arrowhead Pharmaceuticals by 90.3% during the third quarter. JPMorgan Chase & Co. now owns 775,717 shares of the biotechnology company’s stock worth $26,754,000 after buying an additional 368,073 shares during the period. Cantor Fitzgerald L. P. grew its holdings in shares of Arrowhead Pharmaceuticals by 14.7% during the third quarter. Cantor Fitzgerald L. P. now owns 19,500 shares of the biotechnology company’s stock worth $673,000 after buying an additional 2,500 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at about $444,000. Finally, Keystone Financial Group purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $276,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals News Summary

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Interim Phase 1/2a obesity data—Arrowhead reported that its RNAi candidates ARO‑INHBE and ARO‑ALK7 produced meaningful reductions in visceral and total fat and, in a small combo cohort, roughly doubled four‑month weight loss when added to tirzepatide. This is the main bullish catalyst behind intraday gains. BusinessWire: Interim Clinical Data
• Positive Sentiment: Health Canada approval—REDEMPLO™ (plozasiran) received a Notice of Compliance for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS), creating a near‑term commercialization milestone and validating Arrowhead’s siRNA platform. BusinessWire: REDEMPLO Approval
• Neutral Sentiment: Unusual options activity—traders bought a large volume of call options (more than double typical levels), signaling speculative or leveraged bullish positioning around the clinical/approval news. That adds short‑term volatility risk. Benzinga: Options Activity
• Negative Sentiment: Proposed capital raise—Arrowhead announced plans to offer $500M of convertible senior notes due 2032 and $200M of common stock (plus underwriter option). That large financing can be dilutive and is weighing on sentiment despite the clinical wins. BusinessWire: Proposed Offerings
• Negative Sentiment: Insider selling—recent filings show sizable sales by COO Patrick O’Brien, insider James Hamilton, and CEO Christopher Anzalone (multiple sales). Large insider disposals can amplify negative sentiment even when executives say sales are routine. AmericanBankingNews: Patrick O’Brien Sells
• Negative Sentiment: Additional insider sale reports—James Hamilton and Christopher Anzalone also filed recent large share sales, increasing investor concern about insiders trimming positions. AmericanBankingNews: James Hamilton Sells
• Negative Sentiment: Data skepticism—some analysts and commentators note small combo cohorts and missing datasets in the obesity update, urging caution on how durable and generalizable the weight‑loss gains are. This fuels profit‑taking after the initial rally. Seeking Alpha: Skeptical Analysis

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.